STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

Michael E. O'Dwyer; Brian J. Druker

doi:10.1016/S1470-2045(00)00149-2

STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

Michael E. O'Dwyer, Brian J. Druker

Oregon Health and Science University

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

68 Citations (Scopus)

Abstract

The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.

Original language	English
Pages (from-to)	207-211
Number of pages	5
Journal	The Lancet Oncology
Volume	1
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(00)00149-2
Publication status	Published - 2000
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(00)00149-2

Cite this

@article{b7b64d156d3149eeb12088613d39835c,

title = "STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia",

abstract = "The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.",

author = "O'Dwyer, \{Michael E.\} and Druker, \{Brian J.\}",

year = "2000",

doi = "10.1016/S1470-2045(00)00149-2",

language = "English",

volume = "1",

pages = "207--211",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - STI571

T2 - An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

AU - O'Dwyer, Michael E.

AU - Druker, Brian J.

PY - 2000

Y1 - 2000

N2 - The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.

AB - The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the causative molecular event in chronic myelogenous leukaemia. Thus, the BCR-ABL tyrosine kinase is an ideal target for pharmacological inhibition. STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have shown the potential of this specifically targeted therapy, and STI571 is emerging as an important new therapeutic agent for chronic myelogenous leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=0034584880&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(00)00149-2

DO - 10.1016/S1470-2045(00)00149-2

M3 - Review article

C2 - 11905636

AN - SCOPUS:0034584880

SN - 1470-2045

VL - 1

SP - 207

EP - 211

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -

STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this